doi:10.3969/j.issn.1673-8640.2022.09.009

Abstract

CLC Number:

R446.1

Figures/Tables 4

References 10

[1]	叶迎春, 年四季, 刘佳佳, 等. IL-33与自身免疫疾病[J]. 中国免疫学杂志, 2015, 31(8):1132-1137.
[2]	XIAO Y, LAI L, CHEN H, et al. Interleukin-33 deficiency exacerbated experimental autoimmune encephalomyelitis with an influence on immune cells and glia cells[J]. Mol Immunol, 2018, 101:550-563. DOI PMID
[3]	THOMPSON A J, BANWELL B L, BARKHOF F, et al. Diagnosis of multiple sclerosis:2017 revisions of the McDonald criteria[J]. Lancet Neurol, 2018, 17(2):162-173. DOI URL
[4]	KURTZKE J F. Rating neurologic impairment in multiple sclerosis:an expanded disability status scale(EDSS)[J]. Neurology, 1983, 33(11):1444-1452. DOI URL
[5]	邱伟, 徐雁. 多发性硬化诊断和治疗中国专家共识(2018版)[J]. 中国神经免疫学和神经病学杂志, 2018, 25(6):387-394.
[6]	ALLAN D, FAIRLIE-CLARKE K J, ELLIOTT C, et al. Role of IL-33 and ST2 signalling pathway in multiple sclerosis:expression by oligodendrocytes and inhibition of myelination in central nervous system[J]. Acta Neuropathol Commun, 2016, 4(1):75. DOI URL
[7]	FAIRLIE-CLARKE K, BARBOUR M, WILSON C, et al. Expression and function of IL-33/ST2 axis in the central nervous system under normal and diseased conditions[J]. Front Immunol, 2018, 9:2596. DOI URL
[8]	JAFARZADEH A, MAHDAVI R, JAMALI M, et al. Increased concentrations of interleukin-33 in the serum and cerebrospinal fluid of patients with multiple sclerosis[J]. Oman Med J, 2016, 31(1):40-45. DOI URL
[9]	GONÇALVES M V M, BRANDÃO W N, LONGO C, et al. Correlation between IL-31 and sCD40L plasma levels in fingolimod-treated patients with relapsing-remitting multiple sclerosis(RRMS)[J]. J Neuroimmunol, 2020, 350:577435. DOI URL
[10]	SHAJARIAN M, ALSAHEBFOSOUL F, ETEMADIFAR M, et al. IL-23 plasma level measurement in relapsing remitting multiple sclerosis(RRMS) patients compared to healthy subjects[J]. Immunol Invest, 2015, 44(1):36-44. DOI URL

组别	血清		脑脊液
组别	例数	IL-33/（pg/mL）	例数	IL-33/（pg/mL）
MS组	122	509.65±97.36^*	30	71.47±17.74^*
男性	42	481.35±98.25^*	9	68.82±31.20^*
女性	80	608.82±61.71^*#	21	79.42±15.40^*
对照组	122	155.45±38.24	30	43.84±6.68
男性	42	135.84±42.37	10	39.42±9.63
女性	80	176.69±61.45	20	46.92±8.16

组别	血清		脑脊液
组别	例数	IL-33/（pg/mL）	例数	IL-33/（pg/mL）
MS组	122	509.65±97.36^*	30	71.47±17.74^*
男性	42	481.35±98.25^*	9	68.82±31.20^*
女性	80	608.82±61.71^*#	21	79.42±15.40^*
对照组	122	155.45±38.24	30	43.84±6.68
男性	42	135.84±42.37	10	39.42±9.63
女性	80	176.69±61.45	20	46.92±8.16

项目	例数	IL-33/（pg/mL）
病程
≤1年	39	457.25±95.26
>1~<5年	68	515.68±89.52
≥5年	15	577.28±103.62^*
治疗方案
IFN-β	14	326.34±137.19
甲基泼尼松龙	36	466.26±121.23
IFN-β+甲基泼尼松龙	72	404.39±91.34

项目	例数	IL-33/（pg/mL）
病程
≤1年	39	457.25±95.26
>1~<5年	68	515.68±89.52
≥5年	15	577.28±103.62^*
治疗方案
IFN-β	14	326.34±137.19
甲基泼尼松龙	36	466.26±121.23
IFN-β+甲基泼尼松龙	72	404.39±91.34

项目	例数	IL-33/（pg/mL）
EDSS评分
≤5分	76	426.46±91.20
>5分	46	587.13±105.40^*
MS类型
RRMS型	94	451.33±82.27
SPMS型	22	601.96±106.12^##
PPMS型	5	578.56±127.59^#

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 10

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.